Abstract

FORMULATION AND IN VITRO EVALUTION OF MATRIX TABLET CONTAINING SILDENAFIL CITRATE

*Ashish bhandari¹, Seema Gosain², Ganesh Kumar Bhatt¹, Preeti Kothiyal¹

¹Shri Guru Ram Rai Institute of Technology & Science P.O. Box - 80, Patel Nagar, Dehradun 248001, Uttarakhand , India.
²Dehradun institute of technology, Mussourie-Diversion Road, Makkawala, Dehradun, Uttarakhand-248009, India.

ABSTRACT

Sildenafil citrate is a selective inhibitor of phosphodiesterase type 5 enzyme (PDE5), it offers potential to treat patients with pulmonary hypertension by selectively inhibiting phosphodiesterase type five pathways in the lung. It is recommended for selected patients with pulmonary arterial hypertension, and has favourable effects on endothelial function. Controlled release matrix tablets of Sildenafil citrate is designed by simplex lattice design and evaluating the relationship and influence of different content levels of HPMC (Hypromellose), Eudragit L100 and Carbopol (Carbomer), in order to achieve a zero-order release of Sildenafil citrate. Tablets were prepared by wet granulation process and evaluated for different pre and post compression parameter, from these matrix tablets drug release was prolonged, leading to achieve an effective therapy with low dosage of the drug, to reduce the frequency of medication.

Keywords: Sildenafil citrate, Pulmonary hypertension, Matrix tablet, HPMC, Eudragit, controlled release.